Introduction
Effective control of many severe bacterial infections has been made possible due to introduction of antibiotics in medicine. However, the fight continues because of growing resistance to antibiotics commonly used in clinical practice [1] .
Essential oils, a diverse group of plant metabolites, seem to be interesting: they have long been used in aromatherapy, dermatology and cosmetics [2] . Nowadays, experimental research confirms the additional pharmaceutical activity of oils. Various essential oils produce pharmacological effects, demonstrating anti-inflammatory, antioxidant and anticancerogenic properties. Their broad and complex activity, along with their synergy of action in combination with antibiotic therapy make them a valued complement to infection therapy in human diseases, not to mention the lack of reports about emergence of resistance mechanisms of bacteria to these compounds [3] [4] [5] [6] . What is of particular interest is that many of them appear to have a wide spectrum of antimicrobial activity against microflora which usually cause intrahospital infections, such as Acinetobacter species.
Opportunistic infections caused by Acinetobacter spp. are of great concern because of multidrug resistance typical to these bacteria. The majority of infections affect the respiratory tract of hospitalised patients [7] . Besides, bacteria may cause meningitis, bacteremia, wound infections and urinary tract infections [8] . The most common Acinetobacter pneumonia happens among at-risk populations such as patients of ICUs (Intensive Care Units) or immunocompromised people. Infections are characterized with a high mortality rate [9] . Acinetobacter baumannii is a particularly serious threat within the hospital environment, both due to its innate and acquired antimicrobial resistance, its tendency for epidemic spread and ability to persist for long time on unanimated surfaces [10, 11] . The Acinetobacter genomic sp. 13TU and sp. 3 and are also responsible for causing nosocomial infections, but to a lesser extent. Phenotypic commercial identification systems do not differentiate among these species efficiently (misidentification of c. 25% of Acinetobacter isolates belonging to the A. calcoaceticus -A. baumannii complex as A. baumannii [12] but using primers for Acinetobacter gyr B gene enable differentiation of the most important clinically strains of Acinetobacter baumannii and Acinetobacter genomic sp. 13TU [13] .
The aim of this work was to investigate the antimicrobial properties of thyme essential oil obtained from thyme (Thymus vulgaris L.) against standard and clinical strains isolated from patients and clinical staff, as well as from the hospital environment.
Experimental Procedures

Bacterial strains
The standard bacterial strain, Acinetobacter baumanii ATCC 19606, used both in the agar dilution method and PCR reactions came from collection of Medical and Sanitary Microbiology Department, Medical University of Lodz. Clinical Acinetobacter isolates were collected from different materials from patients (29 isolates) and their environment (n=1). They came from the wards of intensive care unit (n=17), orthopaedics (n=3), nephrology (n=3), neurology (n=1), cardiology (n=1), surgery (n=1), urology (n=1), laryngology (n=1) and outpatient clinic (n=1) from one of Lodz hospitals. Clinical bacterial strains were isolated from bronchial washings (n=8), urine (n=6), wounds (n=4), intubation tubes (n=4), drain (n=2), bedsore (n=2), respiratory exudates (n=1), abdominal exudates (n=1) and ear (n=1). One strain came from environmental swab. Both standard and clinical strains were stored at -70°C for further investigation.
Bacteriological media
Several microbiological media were used including Columbia Agar (bioMerieux, France), McConkey Agar (Graso, Poland), Muller Hinton Agar II (bioMerieux, France).
Essential oil and its analysis
Commercial essential oil was purchased from the manufacturer and analyzed by GC-FID-MS in the Institute of General Food Chemistry, Technical University of Lodz, using a Trace GC Ultra apparatus (Thermo Electron Corporation) with FID and MS DSQ II detectors and FID-MS splitter (SGE). The standard and clinical strains used for oil activity testing were cultivated on Columbia agar medium and incubated at 37°C for 48 h in aerobic conditions. Bacterial suspensions with an optical density of 0.5 McFarland scale were prepared. bioMerieux densitometer was used.
Antibacterial analysis of oil activity was carried out by using agar dilution. The essential oil was diluted in ethanol. This solution was mixed with a nutrient broth to obtain concentrations from 0.125 to 1 µl/ml and poured into petri dishes. Inoculum containing 1.5 × 10
8 CFU (0.1 ml) per spot was seeded upon the surface of agar with various oil concentrations, as well as upon that with no oil added (strains growth control). Minimal Inhibitory Concentration (MIC) was determined after 5 days of incubation at 37°C in aerobic conditions. Antibacterial analysis of oil activity was performed three times independently.
Phenotypic and genetic identification of bacterial strains
Acinetobacter strains were identified to the genus by using standard microbiological methods. Speciation was performed with the Vitek system and then confirmed by PCR for Acinetobacter gyrB gene [13] . Bacterial DNA was isolated with a Genomic Mini Kit (A&A Biotechnology, Poland). PCR reactions were carried out in a total volume of 25 μl in a Biometra cycler. The mixture consisted of 0.5 U Hypernova DNA polymerase (DNA Gdańsk), 600 nM of each primer [13] (IBB, Warsaw), 2 mM MgCl 2 (DNA Gdańsk), 2.5 μl PCR buffer and 400 μM dNTP (Fermentas). The products were separated by 1.4% agarose gel (Prona) in 1xTAE buffer (Fermentas) and stained with ethidium bromide (Sigma).
Susceptibility testing
The following antibiotics and chemioterapeutics (Becton Dickinson) were used for susceptibility testing of 
Statistical analysis
Statistical significance was evaluated by one-way nonparametric analysis of variance (ANOVA) (Kruskal -Wallis) and the Sheffe test. The differences were considered significant when the probability of the zero hypothesis was less than 5% (P<0.05).
Results
Phenotypic and genetic identification
It was shown that not all Acinetobacter strains determined as A. baumanii by using Vitek system were assigned to that species by using PCR with primers for gyrB gene. 16 isolates assigned to the species A. baumannii turned out to be Acinetobacter genomic species 13TU. What is more, there were 7 isolates which proved to be other than A. baumannii and Acinetobacter genomic species 13TU strains, which had been determined previously as A. baumannii strains. Incubation at 41°C and 44°C revealed that among these strains there were no genomic sp. 3 isolates. Two isolates described biochemically as A. lwoffii yielded no products in PCR for gyrB gene.
Susceptibility testing
It was revealed that most of the Acinetobacter baumannii clinical strains were resistant to many antibiotics and chemioterapeutics. An especially high number of isolates were resistant to amikacin (43.3%), aztreonam (63.3%), cefotaxim (70%) as well as ciprofloxacin (86.6%), piperacillin/tazobactam (46.6%) and tetracycline (76.7%). It was shown that the most resistant microorganisms were isolated from bronchial secretions and intubation tubes. Two strains of A. baumannii (from bronchial washings and wound) and two genomic species 13TU (from bronchial washings) were susceptible only to one antibiotic -meropenem.
Three other (from bronchial washings, intubation tube and vascular catheter) showed susceptibility to two antibiotics -ampicillin/sulbactam and imipenem. Most of the Acinetobacter strains were multiresistant, only A. lwoffii isolates showed a high susceptibility to tested drugs. What is more, A. baumannii strains and genomic species 13TU were more resistant than other isolates of Acinetobacter. Table 1 shows general characteristics of Acinetobacter isolates and Table 2 the number of isolates resistant to antibiotics.
Chemical composition of the tested oil
The analysis of the tested essential oil derived from T. vulgaris revealed that its composition meets the requirements of the Polish Farmacopoeia VIII and the European Farmacopoeia [17, 18] . The content of thymol amounts to 38.1%, and carvacrol to 2.3%. Besides, there were other prevailing compounds as p-Cymene (29.1%), γ-terpinene (5.2%) and linalool (3.7%).
The chemical composition of the tested oil is shown in Table 3 .
The activity of thyme oil against Acinetobacter sp. strains
The values of the MIC for Acinetobacter spp. were between 0.25 and 1.0 µl/ml. MIC was 0.25 µl/ml for the standard strain of Acinetobacter baumanii ATCC 19606 and 3 clinical strains. Most Acinetobacter spp. strains (n=24) were sensitive to 0.5 µl/ml oil concentration. [20] .
Thyme as a wild plant is common in the Iberian Peninsula, France, Italy, Greece and North Africa. It is cultivated throughout Europe and America. A lot of chemotypes have been identified in red thyme T. vulgaris, the most important are thymol chemotype (65% thymol, 5-10% carvacrol) and carvacrol chemotype (85% carvacrol, 1-5% thymol) [21] . According to the requirements of the FP and FE the oil should contain thymol (36-55%) and carvacrol (1-4%). The Polish Pharmacopeia and European Pharmacopoeia [17, 18] show the flourishing, fresh herb of Thymus vulgaris L and Thymus zygis Loefl. ex L. as a source of the essential oil of thyme. The thyme oil used by us was obtained from Thymus vulgaris L. by the Technical University of Lodz and meets the requirements of the Polish Pharmacopoeia VIII and European Pharmacopoeia. In our study, the oil showed antimicrobial activity against standard and clinical strains of Acinetobacter sp. Our results show that thyme oil has strong antimicrobial properties against all tested strains. The activity is due to the high content of phenolic compounds with the antibacterial properties such as thymol and carvacrol which are over 40% of the ingredients of the oil [2] . In our tests, clinical strains of Acinetobacter sp. were sensitive to thyme oil at concentrations of 0.25, 0.5, 0.75 and 1 µl/ml, therefore relatively low compared to the high concentrations of antibiotics usually required. MIC for most strains (n=24) was 0.5 µl/ml. These strains came from diverse materials and hospital wards. They belonged both to genomic sp. 13TU and Acinetobacter baumannii as well as to other species. As far as susceptibility to antibiotics was concerned, most isolates were resistant to ATM (n=23), CTX (n=24), CIP (n=29), TIM (n=21), STX (n=25) and TE (n=25). However, most strains were susceptible to ampicillin/sulbactam, tobramicin and cefoxitin. Both strains with MIC at 1 µl/ml were isolated from urine but in different wards (nephrology and ICU). They were also susceptible to several antibiotics: SAM, GM, IMP, TIM, NN, SXT. The only isolate for which the MIC was 0.75 µl/ml, isolated from a wound in the surgery ward, was susceptible to SAM, ATM, GM, CAZ, MEM, NN.
Resistance to meropenem is more and more often found among Acinetobacter strains [22] , but in our study there were no isolates demonstrating that kind of resistance. Because carbapenems are thought to be the only independent risk factor for the appearance of imipenem resistant MDRAB (Multidrug Resistant A. baumannii), other antimicrobial agents should be evaluated for the efficacy of eradicating those strains sensitive to imipenem, but multiresistant [19] . As other authors suggested, beside tigecycline, old antibiotics like aminoglycosides and colistin will have to be re-employed. What is more, there is a need to search for drugs such as essential plant oils rather than antibiotics and chemotherapeutics. Additionally other procedures such as reducing selection pressure by shortening duration of treatment should be used [23, 24] .
According to many manuscripts, multidrug resistant Acinetobacter baumannii is defined as resistant to more than three classes of antibiotics [25, 26] . Dent et al. reported that 58% of the A. baumannii strains were resistant to imipenem, amikacin, and ampicillinsulbactam, which were previously very effective against A. baumannii. It was later reported that only 17% of the isolates were sensitive to all three of the above antimicrobial agents and 46% of the isolates were resistant to all commonly-used antibiotics [25] . Resistant strains were a significant problem also in our study. However, 13% of the strains were resistant at the same time to IMP, AN, SAM, but ampicillin/sulbactam remained generally effective against tested isolates and 16.6% of the strains were susceptible to all three drugs. Our tests revealed that 13 isolates (43%) were resistant to imipenem and 26 of 30 were resistant to most tested drugs. This study is limited because it did not include the high number of strains tested for antibiotic susceptibility but the goal was to determine the impact of thyme oil on Acinetobacter strains. Most of the resistant isolates occurred in the ICU and the major site of isolation was the respiratory tract, which is in accordance with the literature [25] . The sites of A. baumannii isolation in ICUs (n=17) were mainly respiratory tract (n=13, 43.3%), wounds (n=2, 6.6%), urinary tract (n=1, 3.3%), and vascular catheters (n=1, 3.3%).
In our investigation 30 Acinetobacter clinical strains were tested for the presence of gyrB gene. Five of 30 clinical strains and standard Acinetobacter baumannii ATCC 19606 strain produced two clear bands, then proved to be A. baumannii strains. All those isolates were biochemically determined to be A. baumannii strains. However, 16 strains identified previously as A. baumannii were proved to be genomic sp. 13TU. These species are very difficult to differentiate with biochemical tests. What is more, seven strains yielded no PCR products for the gyrB gene even though being earlier classified as A. baumannii isolates. Two strains determined as A. lwoffii also failed to produce PCR products. Regarding susceptibility to thyme oil there were no significant differences in MICs between species of Acinetobacter.
In accordance with the literature, Thymus vulgaris L oil showed an inhibitory effect against the growth of Staphylococcus aureus strains isolated from respiratory infections. Using the disc-diffusion method an MIC of 0.0125 µl/ml was obtained for thyme oil and also for Cinnamomum zeylanicum Blume. and Syzygium aromaticum (L.) Merr. & Perry, rich in phenolic compounds. The tested strains of S. aureus sensitive to this essential oil were resistant to oxacillin, gentamicin and tobramycin and many of them to norfloxacin [27] . Studies on the antimicrobial properties of the essential oil obtained from Thymus fontanesii Boiss. Et Reut. containing carvacrol demonstrated its very strong activity against Gram-negative bacteria, clinical strains of Escherichia coli, with an MIC of 0.35 µl/ml [28] . The action of Thymus spinulosus Ten. essential oil, having much a lower content of active phenolic compounds (thymol) compared to the oil derived from Thymus vulgaris L., was much weaker against blue pus bacilli. The obtained MIC values were within the limits of 4.5 -9.0 ml/ml, which was in accordance with the literature [29] . The essential oil of Origanum vulgare, containing phenols as predominant compounds, in low concentration was capable of preventing the growth of the nosocomial bacteria A. baumannii, P. aeruginosa, (resistant to ceftazidime and carbapenems), E. coli, K. pneumonia, E. faecalis, extended spectrum betalactamases producers (ESBL) and methicillin resistant S. aureus (MRSA) [30] . To our knowledge, this study is the first one presenting the considerable activity of essential thyme oil against diverse clinical species of Acinetobacter, which is becoming more crucial because of the increasing resistance of those species to commonly-used antibiotics. More importantly, thyme essential oil may be used as a drug in respiratory tract infections often caused by Acinetobacter spp. Essential oils are to be an excellent alternative for synthetic preparations and used in combination with antibiotics may prevent antibiotic-resistant strain development.
Conclusions
Thyme oil obtained from Thymus vulgaris L.:
-shows very strong activity against standard and clinical strains belonging to Acinetobacter genus.
-is active at low concentrations against clinical strains resistant to most tested antibiotics.
